QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The goal of this study is to learn more about the efficacy and safety of BMS-986363 in participants with relapsed or refractory multiple myeloma. 

Trial status

Accepting patients

Phase
Phase 2
Enrollment
150
Last Updated
1 week ago
Am I Eligible

Participating Centers

There are 34 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BMS-986393 (CC-95266)

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

BMS-986393

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.